Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Change in Cash (2019 - 2025)

Pulmonx (LUNG) has disclosed Change in Cash for 7 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 818.54% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.2 million, a 141.88% increase, with the full-year FY2024 number at -$12.6 million, up 30.58% from a year prior.
  • Change in Cash was $1.1 million for Q3 2025 at Pulmonx, up from $913000.0 in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $8.7 million in Q1 2023 to a low of -$39.6 million in Q4 2021.
  • A 5-year average of -$8.2 million and a median of -$8.6 million in 2023 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: crashed 1406.63% in 2021, then skyrocketed 818.54% in 2025.
  • Pulmonx's Change in Cash stood at -$39.6 million in 2021, then skyrocketed by 73.06% to -$10.7 million in 2022, then fell by 6.85% to -$11.4 million in 2023, then soared by 166.61% to $7.6 million in 2024, then tumbled by 85.71% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Change in Cash are $1.1 million (Q3 2025), $913000.0 (Q2 2025), and $3.6 million (Q1 2025).